CMND
Clearmind Medicine Inc.$3.17
LiveJun 01, 2026
Market cap
$3.23M
52w range
2.10 – 524.00
P / E
—
EPS
—
Volume
1.04M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Clearmind Medicine Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for CMND.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -11.45% | +24.80% | -51.82% | -71.95% | -94.50% | -82.49% | -99.16% | -99.95% | -100.00% | -100.00% | -100.00% |
Aftermarket
LiveLast trade
$2.89
200 sh
Bid
$2.85
2 sh
Ask
$2.99
2 sh
Spread
$0.140
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorderglobenewswire.com·May 12, 2026
- Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorderglobenewswire.com·May 12, 2026
- Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorderglobenewswire.com·May 12, 2026
- Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorderglobenewswire.com·May 12, 2026
- Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trialglobenewswire.com·May 11, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|